Seite 1 von 18
neuester Beitrag: 24.05.20 21:01
eröffnet am: 06.01.14 21:53 von: Masterbroker. Anzahl Beiträge: 443
neuester Beitrag: 24.05.20 21:01 von: sario Leser gesamt: 67600
davon Heute: 6
bewertet mit 3 Sternen

Seite: 1 | 2 | 3 | 4 |
16 | 17 | 18 | 18   

06.01.14 21:53

3007 Postings, 2347 Tage MasterbrokerUSAAMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK

Nächste Rakette ???  
Seite: 1 | 2 | 3 | 4 |
16 | 17 | 18 | 18   
417 Postings ausgeblendet.

23.04.20 10:54

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

Ich bin sehr zuversichtlich dass der Appeal erfolgreich sein wird, eine Jury mit 3 hoffentlich unabhänigen Richtern/innen die Ahnung  von der Sachlage haben sollen, werden feststellen das "honorable judge DU"
factual and procedur erros gemacht hat.....
Yes we hope....

Traurig, dass es soweit kommen musste, aber wo es um viel Geld geht, ist immer Korruption..... dabei  

26.04.20 17:27

1957 Postings, 3537 Tage Planetpaprikaes heißt

"It's confirmed the new lead counsel will be Fish & Richardson, on Forbes list of america's top law firms...."
Search on PACER April 21, 2020
"Entry of appearance for Jonathan E. Singer as principal counsel for Appellants Amarin Pharma, Inc."

WENN dem wirklich so ist :
Mr. Singer is annually named one of the nation?s finest life sciences trial attorneys and is an expert in proceedings under the Hatch-Waxman Act. His clients consistently praise his innovative and ground-breaking work and over the past two decades, he has successfully handled dozens of cases covering all aspects of the life sciences.  In addition to his courtroom work, Mr. Singer regularly teaches life sciences trial and patent practice courses in the U.S. and Europe.

"Forbes list america's top corporate law firms"
"Last month, Fish was named one of three elite "IP Litigation Powerhouses" in the prestigious BTI Litigation Outlook 2020 survey. Fish was the only firm to appear on the list in two consecutive years. Fish was also named one of 10 "Awesome Opponents" in BTI's list of the "Most Feared Law Firms in Litigation." The BTI survey is based solely on in-depth telephone interviews with leading litigation decision-makers at large organizations with $1 billion or more in revenue."

Perkins Coie ist damit für mich noch nicht gegessen und eigentlich mein Favorit.
Oder WAREN diese bisher tätig für Amarin ? Weiß jemand von den Mitlesenden hier mehr ?
Ich halte die Wahl der Rechtvertretung für enorm, enorm wichtig...


27.04.20 15:56

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

2 Top Biotech Stocks Under $10
Amarin and Atara Biotherapeutics could both be diamonds in the rough.
George Budwell
George Budwell
Apr 27, 2020 at 7:56AM
Author Bio

Stocks priced below $10 a share can be a mixed bag. Low share prices are often indicative of companies with poor fundamentals, a weak near-term outlook, and a large number of outstanding shares. These types of equities, in turn, tend to be exceptionally risky and highly volatile from a price standpoint. But there are a few significant upsides to buying stocks in the $5 to $10 range.

Low-priced equities, on occasion, can deliver substantial returns on capital within an exceedingly short period. What's more, it's far easier to build a position in round lots of 100 shares at a time. By doing so, investors can reduce their risk profile and generate immediate cash from the position by selling call options. While selling calls can cap the maximum return from a low-priced equity, this strategy also ensures that you won't walk away empty-handed in a worst-case scenario.
A man wearing sunglasses while throwing money into the air.

Image source: Getty Images.

Which companies with share prices under $10 should investors be paying attention to right now? Two of the best low-priced equities at the moment are Amarin (NASDAQ:AMRN) and Atara Biotherapeutics. (NASDAQ:ATRA). These two biotech stocks have been heating up over the course of April and both are seemingly undervalued relative to their long-term outlook. Here's a snapshot of the pros and cons of each company.
Amarin: A bet on a full-blown comeback

Amarin is a single-product, commercial-stage biopharma. The company's value proposition thus begins and ends with its prescription omega-3 treatment Vascepa. Last year, the drug gained a major label expansion as a treatment for patients taking statins but who are still at risk of cardiovascular disease. This new indication was thought to be worth at least $2 billion in annual sales, and possibly quite a bit more. Unfortunately, a U.S. District Court stripped Vascepa of its patent protection in March, causing Amarin's shares to collapse.

Thanks to the growing optimism that this decision will be overturned upon appeal, Amarin's shares have gained 88% in the nearly four weeks since this adverse ruling. This rapid recovery has also been fueled by the fact that Vascepa could still achieve blockbuster status, regardless of this patent ruling, due to its healthy commercial opportunity in former U.S. territories.  

What are the risks and rewards? With a successful appeal in hand, Amarin's shares should rise by at least another 70% from current levels in light of where this stock was trading prior to this black swan event. If this appeal fails, however, Amarin should ultimately settle at around $8 a share -- based on Vascepa's commercial opportunity in the former territories and the average pre-pandemic premium for a commercial-stage biopharma stock. So, even in a worst-case scenario, Amarin's shares are arguably still undervalued right now.    
Atara: A make-or-break moment is on the way

Atara is a cell-based immunotherapy company. The company's main selling point to investors is its leadership position in the field of off-the-shelf T-cell therapies for cancer, autoimmune disorders, and viral infections. Atara's strategy centers around launching the first off-the-shelf T-cell therapy, dubbed tab-cel, for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease as soon as next year. A regulatory filing for this first-of-its-kind therapy is slated for the second half of 2020.

Although tab-cel's peak sales are expected to be rather modest at around $140 million a year, the company's second product candidate, ATA188, could be a megablockbuster as a novel treatment for patients with progressive multiple sclerosis. What's more, Atara's buyout value should skyrocket if its cell-based platform is validated with a successful regulatory filing for tab-cel. There are several big pharmas and blue-chip biotech companies racing to develop similar technologies after all.

What's the risk? While Atara does have the inside track for becoming the first company to bring an off-the-shelf T-cell therapy to market, there's also no guarantee that this novel therapy will get a green light from regulators. That's a significant risk factor to be sure. Atara's shares, in short, will surely take a huge step backward if tab-cel stumbles in the clinic or fails to win over regulators. On the flip side, this small-cap biotech stock does have the potential to double (or possibly triple) in value in the event that tab-cel does live up to expectations.

Bottom line: Atara is the epitome of a high-risk, high-reward clinical-stage biotech stock. Invest accordingly.    

27.04.20 17:03

518 Postings, 1894 Tage RV10Nervt solangsam!

28.04.20 10:36

483 Postings, 1813 Tage oli25was?

28.04.20 10:59

199 Postings, 2980 Tage sarioWeil Amerin steigt ;)

28.04.20 11:01

483 Postings, 1813 Tage oli25also ich finds gut. :)

28.04.20 16:03

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

RV 10 hat keine Ahnung.......

Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020
GlobeNewswire?April 28, 2020

DUBLIN, Ireland and BRIDGEWATER, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2020 financial results and provide an operational update on Thursday, April 30, 2020, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.

Conference Call and Webcast Information:

Amarin will host a conference call April 30, 2020, at 7:30 a.m. ET to discuss this information. The conference call can be heard live on the investor relations section of the company's website at, or via telephone by dialing 877-407-8133 within the United States, 201-689-8040 from outside the United States, or by using the call back feature at A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-481-4010, PIN: 34453. A replay of the call will also be available through the company's website shortly after the call.

To Ask Questions:

During the teleconference, following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. Participants in the live teleconference will be provided an opportunity to ask questions. Investors may also e-mail their questions to Email questions will be accepted until Wednesday, April 29, 2020 at 4:00 p.m. ET.

About Amarin

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin?s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union and the Middle East. For more information about Amarin, visit

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (, the investor relations website (, including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin?s investor relations website and may include social media channels. The contents of Amarin?s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor and Media Inquiries:
Elisabeth Schwartz
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315 (investor inquiries) (media inquiries)

Lee M. Stern
Solebury Trout
In U.S.: +1 (646) 378-2992  

30.04.20 11:12

636 Postings, 1261 Tage Ice-Nine comingcourt ruling

Dann hoffe ich mal, das es nicht viel länger als Q1 2021 dauern wird, bis eine Entscheidung fällt. Aus der heutigen Pressemitteilung zu den Q1 Ergebnissen:

This proposed timing should facilitate a hearing in Q3 2020 (or perhaps early Q4 2020) and position the court to rule thereafter potentially in 2020 or in early 2021.  

30.04.20 18:45

5461 Postings, 1082 Tage VassagoAMRN 7.65$ (-7%)

Zahlen für Q1/20

  • Umsätze 155 Mio. $ (+112% zu Q1/19)
  • Berufungsverfahren im Patentrechtsstreit soll beschleunigt werden
  • Anhörung in Q3/20 oder im frühen Q4/20 geplant
  • Gerichtsentscheidung könnte dann 2020 oder Anfang 2021 erfolgen


01.05.20 13:14

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

Anal-ysten erhöhen nach einem Monat das Kursziel auf das Doppelte, es scheint als hätten sich die Klienten zum Teil eingedeckt, Dreckspack:

Citi doubles Amarin price target to $12 ahead of appeal decision Citi analyst Joel Beatty doubled the firm's price target on Amarin to $12 from $6 and keeps a Buy rating on the shares. The stock closed Thursday down 65c to $7.61. Beatty sees a "relatively high likelihood" of share upside from a European partnership in the second half of 2020, and also believes competitors are unlikely to launch a generic version of Vascepa before the appeal decision expected by the end of the year. While acknowledging a high risk to the stock from the appeal decision, he believes his 20%-40% probability of success on appeal for Amarin still provides a "favorable enough risk/reward" to buy the stock at the current price. Shares of Amarin are worth $24 on an appeal win, and $7 on a loss, Beatty tells investors in a research note.

Read more at:  

02.05.20 16:42

1957 Postings, 3537 Tage Planetpaprikakz 51 $

:-) hat gestern ein analyst von sich gegeben, trau mich fast nicht, den link hier einzustellen :-)
schönes we !!  

02.05.20 17:47

2150 Postings, 4106 Tage MagnetfeldfredyAmarin


Amarin hired good attorney for Vascepa appeal, says H.C. Wainwright 07:14 AMRN H.C. Wainwright analyst Andrew Fein believes Amarin (AMRN) hired a good attorney for the Vascepa patent litigation appeal process in Jonathan Singer, head of the life sciences litigation practice at intellectual property litigation leader Fish & Richardson. In consultation with a patent attorney, Fein learned that Singer has tried several high profile cases, including being on the team that won an appeal on behalf of Gilead Sciences (GILD) regarding the hepatitis C drug sofosbuvir, in which the judge overturned a $2.5B jury verdict and the Federal Circuit affirmed. The analyst reiterates a Buy rating on Amarin with a $51 price target. While Fein thinks Vascepa growth can continue in the near term, he believes the combination of in-person Vascepa sales calls being suspended and reduced patient visits to physician offices amid the COVID-19 pandemic can have a continued impact on new prescriptions looking ahead to Q2.

Read more at:  

04.05.20 15:26

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

Nicht nur Wainwright sieht großes Potential, auch Roth Capital sieht Amarin als "strong buy" mit einem Kursziel von US Dollar 31, also 4-5 Bagger:

Amarin a 'strong buy' ahead of federal circuit ruling, says Roth Capital Roth Capital analyst Yasmeen Rahimi sees COVID-19 disruptions as only a "minor distraction" from Amarin's continued commercial rollout of Vascepa. Although the pandemic has made it difficult for the company to fully take advantage of its sales expansion started in 2019, Amarin has taken innovative steps to keep interactions between sales reps and doctors, Rahimi tells investors in a research note. Further, the analyst notes that Amarin bumped up the timeline for a Vascepa appeals decision, with a hearing as early as Q3 and ruling thereafter by the end of 2020 or early 2021. With an expedited timeframe for its appeal, Amarin is a "strong buy" ahead of a potential federal circuit ruling, contends Rahimi. Following a deep dive with a "patent law guru," the analyst sees a high probability of success for the company on appeal. Alongside the "strategic optionality" being explored for Vascepa commercialization in Europe and a "strong resiliency" in the COVID crisis, Amarin shares offer "significant upside" potential for 2020, says Rahimi. The analyst keeps a Buy rating on the name with a $31 price target.:D The stock closed Friday at $7.34. Read more at:

Amarin - The Science Of Lipid Therapy | - Vollständige Diskussion unter:  

05.05.20 16:38

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

Northland starts Amarin at Outperform amid 'major paradigm shift' 10:13 AMRN Northland analyst Carl Byrnes initiated coverage of Amarin with an Outperform rating and $15 price target. The stock closed Monday up 28c to $7.62. The expanded label given to Vascepa represents a "major paradigm shift" in lipid management, addressing "sizeable" market opportunities in the U.S., Europe and the rest of the world, Byrnes tells investors in a research note. And while the ongoing patent litigation represents a "major risk," potential generic entrants will not be able to procure sufficient quantities of FDA-grade icosapent ethyl to pose a material commercial threat, predicts the analyst. Byrnes anticipates a ruling in the patent appeal in late 2020 or early 2021. The risk/reward profile of Amarin shares is compelling, says the analyst.

Read more at:  

05.05.20 22:42

199 Postings, 2980 Tage sarioVielen Dank für die Recherche!

14.05.20 16:23

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

Der Appealbrief von Amarin scheint gut zu sein:

Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
With Amarin having filed its opening appeal brief with the U.S. Court of Appeals for the Federal Circuit, H.C. Wainwright analyst Andrew Fein consulted with a patent attorney on initial perspectives. The patent attorney concluded that Amarin has done a thorough job presenting its case and effectively presented its opening shot in the best light possible, Fein tells investors in a research note. The attorney further believed the brief explained the Vascepa technology and the basis of the invention thoroughly, why it was needed and the approach the inventor took to solve the problem of lowering triglycerides in patients with severe hyperlipidemia without raisi ng LDLs, adds the analyst. Fein points out that Amarin essentially has two main lines of argument: that the court erred in finding a prima facie case of obviousness because it did not apply the correct analytical framework and erred in its approach to secondary considerations. Fein's consulted attorney found Amarin's second line of argument compelling, both on the merits and on the clarity and force of argument. That said, the company only needs to be right on one, Fein adds. He keeps a Buy rating on Amarin with a $51 price target  

15.05.20 07:35

2150 Postings, 4106 Tage MagnetfeldfredyAmarin

Sensationelle Ergebnisse gestern und der Kurs macht fast Nichts, dank dem krassen Fehlurteil von Richterin Du.....

Amarin Corporation plc (AMRN)EQUITY RESEARCHMay 14, 2020Price: $7.42Price Target: $35.00Rating: OverweightKey Statistics:SymbolNASDAQ: AMRN52-Week Range$3.95 - $26.12Market Cap (M)2,860.3ADV (3 mo)15,538,966Shares Out (M)385.5Research Analysts:Louise Chen212-915-1794Louise.Chen@cantor.comBrandon Folkes, CFA212-294-8081Brandon.Folkes@cantor.comJennifer Kim212-829-4860Jennifer.Kim@cantor.comCarvey Leung212-915-1917Carvey.Leung@cantor.comOne-Year Price History3025201510505/1908/1911/1902/2005/20AMRNCreated by BlueMatrixQuick TakeSteady Stream of Positive Data Supporting VascepaDoesn't Skip a BeatTakeawaysnToday  (5/14),  AMRN  announced  data  from  the  REDUCE-IT  study  presented  byBenjamin  E.  Peterson,  M.D.,  Brigham  and  Women?s  Hospital  Heart  &  VascularCenter  and  Harvard  Medical  School,  at  the  Society  for  Cardiovascular  Angiography&  Interventions  2020  Scientific  Sessions.  The  study  showed  that  administrationof  4g/day  of  Vascepa  resulted  in  a  significant  34%  reduction  in  first  coronaryrevascularizations  versus  placebo  (p<0.0001).  Similar  reductions  of  36%  wereobserved in total, or first and subsequent, revascularizations (p<0.0001). These datasupport our OW rating on the stock and our belief that the peak sales potential ofVascepa is still underappreciated. Please see here for the post hoc analyses.nCoronary revascularization procedures are invasive, carry multiple risks, and can havesignificant direct and indirect costs. Patients with elevated triglycerides, despite statintherapy, have increased risk for ischemic events, including coronary revascularizations.These procedures, whether pre-scheduled or performed in an emergency, often resultin additional time spent in a healthcare setting.nThe  analyses  from  the  REDUCE-IT  study  included  several  types  of  coronaryrevascularization   events   in   statin-treated   patients   with   persistent   elevatedtriglycerides (135-499mg/dL), who also had either cardiovascular disease or diabetesand  additional  cardiovascular  risk  factors.  Prespecified  tertiary  endpoint  analysesshowed  that  times  to  first  revascularization  events  were  significantly  reduced  byVascepa versus placebo across subtypes of intervention, including urgent, emergent,and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02),and 32% (p<0.0001), respectively. In post hoc analyses, Vascepa significantly reducedpercutaneous  coronary  intervention  (PCI)  by  32%  (p<0.0001)  and  coronary  arterybypass grafting (CABG) by 39% relative to placebo (p=0.0005).nREDUCE-IT  was  not  specifically  powered  to  examine  individual  cardiovascularendpoints;  therefore,  p-values  presented  for  these  revascularization  analyses  arenominal and exploratory with no adjustment for multiple comparisons. In addition,coronary revascularization as an endpoint can sometimes be considered subjective;however,  these  endpoints  were  adjudicated  by  an  independent,  blinded  clinicalendpoint  committee.  Results  from  the  total  coronary  revascularization  eventsanalyses  are  consistent  across  the  various  recurrent  event  statistical  models  andare also consistent with the first coronary revascularization events results. Together,the REDUCE-IT first and total coronary revascularization events results support therobustness  and  consistency  of  the  clinical  benefit  of  Vascepa  therapy  in  reducingcoronary revascularization.Investment ThesisWe  reaffirm  our  OW  rating  and  think  the  peak  sales  potential  of  Vascepa  isunderappreciated. Therefore, upward earnings revisions to levels not reflected in FactSetconsensus expectations should drive AMRN shares higher.The Disclosure Section may be found on pages 3 - 4.
ValuationWe continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35.RisksAmarin  Corporation  is  a  commercial-stage  company,  although  it  is  still  involved  in  theclinical pathway to expand the label for its currently approved product. As such, Amarinis subject to certain risks.Regulatory  Risk:  Actual  clinical  results  and  the  FDA's  conclusions  may  deviate  fromexpectations.  Many  of  our  model  assumptions  are  based  on  incomplete  clinical  data.Ultimately,  it  is  the  regulatory  bodies  of  the  Food  &  Drug  Administration  (FDA)  andEuropean Medicines Agency (EMA) that will determine the approval process of the clinicalfind  

15.05.20 08:42

424 Postings, 1187 Tage ahoffmann19@Magnetfeldfre.:

Danke für Deine Infos. Das wäre ja ein Traum, wenn sich die Richterin geirrt hat und die Berufung zugunsten von Amarin ausgehen würde ! UND dieses Kursziel wäre natürlich auch ein Traum ! Leider wird sich das Thema wohl noch sehr lange hinziehen ! Ich bin zu 7 Euro mit einer ersten kleinen Position eingestiegen. Überlege aber, hier nochmal nachzulegen.... Kann halt nur nicht die Sachlage und die erste Entscheidung der Richterin richtig einschätzen !?  

22.05.20 13:51

199 Postings, 2980 Tage sariowas ist los hier heute? hmmm

22.05.20 14:12

636 Postings, 1261 Tage Ice-Nine comingRe '438

Generkia heute von der FDA approved.

Heißt aber letztlich nicht, dass die Company das Produkt auch noch vor der Gerichtsentscheidung auf den Markt bringt. Dennoch verstimmt das natürlich den Markt und die Investoren.


22.05.20 16:54

5461 Postings, 1082 Tage VassagoAMRN 7.30$

FDA erteilt Hikma Pharmaceuticals die Zulassung für deren Vascepa® Generikum

Eine Zulassung ist noch keine Produktion, ich glaube Hikma wird die Gerichtsentscheidung erstmal abwarten, bevor sie auch nur einen Dollar in die Hand nehmen werden um die notwendigen Produktionsanlagen zu entwickeln. Die Errichtung würde ca. 6 Monate dauern. Die Berufungsentscheidung wird wahrscheinlich frühstens im Dezember 2020 getroffen. (siehe Posting #323)


22.05.20 22:31

199 Postings, 2980 Tage sarioTja...hat sich ja früh beruhigt...

beruhige mich auch :)
an euch: schönes Wochenende  

24.05.20 11:56

1957 Postings, 3537 Tage PlanetpaprikaBeruhigt ? Lesen.

Potential combo therapy with Remdesivir !!!

The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group.
Based on our current understanding of the biological effects of a COVID-19 infection, including that patients at high risk of cardiovascular disease are at higher risk of mortality and severe effects from a COVID-19 infection, and based on data related to the mechanism of action and effects of VASCEPA in lowering cardiovascular risk in certain high-risk patients, it is believed that VASCEPA could play a beneficial clinical role in helping patients infected by the virus.

The clinical effects of VASCEPA are multi-factorial...

Und zu Hikma, das ist keine Neuigkeit in dem Sinne, sondern Hikma sind einfach die Ersten von weiteren Generika Herstellern, die, wie Hikma, seit 2016 auf der Matte stehen. So sieht
Cantor Fitzgerald analyst Louise Chen es  ?still positive? on Amarin, DESPITE the FDA approval of the Hikma generic. She said it seemed UNLIKELY that Hikma would begin selling its generic before a decision on the appeal, and thinks AMARIN WILL WIN IT APPEAL. She also noted the Vascepa supply chain is complicated, and said it could be hard for Hikma to manufacture a large amount of the drug."

Alles nur meine Meinung. KZ 15-35 $$... :-)


24.05.20 21:01

199 Postings, 2980 Tage sario#442 Danke

nett zu lesen, sehr interessant!  

Seite: 1 | 2 | 3 | 4 |
16 | 17 | 18 | 18   
   Antwort einfügen - nach oben

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!


Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Deutsche Bank AG514000
Wirecard AG747206
Scout24 AGA12DM8
Lufthansa AG823212
Daimler AG710000
Airbus SE (ex EADS)938914
BioNTech SE (spons. ADRs)A2PSR2
ITM Power plcA0B57L
Carnival Corp & plc paired120100
Shell (Royal Dutch Shell) (A)A0D94M